Short answer: both raise NAD+ in humans. NR (Nicotinamide riboside) has the longer trial record and is one step further from NAD+ in the pathway; NMN is one step closer and has the more recent functional-outcome data. The "one step closer must be better" argument sounds decisive and is weaker than it appears, because NMN is thought to be dephosphorylated back to NR to cross the cell membrane in the first place.
Where each sits in the pathway
The salvage pathway is how cells recycle nicotinamide back into NAD+ rather than building it from scratch. Simplified, the sequence runs: nicotinamide riboside → NMN → NAD+. NR is converted to NMN by NR kinases; NMN is converted to NAD+ by NMNAT enzymes.
So NMN is literally one enzymatic step from NAD+ and NR is two. That is the entire basis of the "NMN is closer" marketing claim, and taken at face value it seems to settle the matter.
Why "closer" does not settle it
The complication is transport. NMN is a phosphorylated molecule, and phosphate groups make membrane crossing difficult. A significant body of work suggests NMN is dephosphorylated to NR outside the cell, transported in as NR, then re-phosphorylated back to NMN inside — which would mean much of an NMN dose passes through the NR form anyway.
A transporter for NMN itself (Slc12a8) has been described in mouse small intestine, so the picture is not settled in either direction. The honest position is that the pathway question is genuinely open, and that neither "NMN is closer so it wins" nor "NMN just becomes NR so it is pointless" is supported well enough to state as fact.
Which is a good reason to judge them on trial data instead of on pathway diagrams.
What the human trials show
NR has the longer record. Trammell and colleagues (2016) established oral bioavailability and dose-dependent NAD+ elevation in humans. Martens and colleagues (2018) ran six weeks of chronic supplementation in healthy middle-aged and older adults, confirming it was well tolerated and effectively stimulated NAD+ metabolism. NR has been through more trials, in more populations, for longer.
NMN has the more striking recent result. Irie and colleagues (2020) established single-dose oral safety in healthy Japanese men. Yoshino and colleagues (2021) then reported that ten weeks of oral NMN improved muscle insulin sensitivity in prediabetic women — a functional physiological outcome rather than a biomarker, which is a meaningfully higher bar.
Neither compound has long-duration outcome trials in healthy adults. Both are supported by short studies with modest participant numbers. Anyone telling you the question is closed is overselling.
The regulatory difference worth knowing
NMN's status as a dietary supplement ingredient in the United States has been contested, following a position that it was excluded because it had been investigated as a new drug. NR does not have that complication. This is a commercial and availability issue rather than a safety finding, but it explains why the two are not equally easy to buy in every market and why some brands carry one and not the other.
How to choose
Choose NR if you want the compound with the largest number of human trials behind it and the least regulatory ambiguity.
Choose NMN if the functional outcome data matters more to you than trial count, and it is available where you are.
The more useful variable is neither. It is whether you take a real dose consistently for long enough to match the trial durations — eight to twelve weeks — rather than switching compounds after three. Dose and adherence dominate the choice between two compounds that both demonstrably raise NAD+.
AE·ORA NMN delivers 500 mg per capsule at 99.9% purity. NAD+ Full Stack takes a different angle, pairing NAD+ with quercetin and resveratrol. See also NMN vs NAD+ and NMN Dosage and Side Effects.
Frequently Asked Questions
Quick answers to the questions readers most often ask.
Is NMN better than NR?
Neither is established as better. NMN is one enzymatic step from NAD+ and NR is two, but NMN is thought to be dephosphorylated to NR to cross the cell membrane, which weakens the 'closer is better' argument. NR has more human trials; NMN has the more recent functional outcome data. Dose and consistency matter more than the choice between them.
What is the difference between NMN and nicotinamide riboside?
They sit at different points in the same salvage pathway: nicotinamide riboside converts to NMN, which converts to NAD+. NR is a riboside; NMN is its phosphorylated form. Both raise NAD+ in human trials.
Does NMN just turn into NR anyway?
Possibly in part. Evidence suggests NMN is dephosphorylated to NR for membrane transport and re-phosphorylated inside the cell, though a dedicated NMN transporter has also been described in mouse intestine. The question is genuinely unresolved, which is why trial data is a better basis for choosing than pathway theory.
Why is NMN harder to buy than NR in the US?
NMN's status as a dietary supplement ingredient has been contested on the basis that it had been investigated as a new drug. Nicotinamide riboside does not carry that complication. It is a regulatory and availability issue rather than a safety finding.
How long should I take NMN or NR before judging it?
Human trials generally run eight to twelve weeks before measuring outcomes. Switching compounds after two or three weeks means never completing a trial-length course of either, which is a more common mistake than choosing the wrong molecule.
References
- Trammell SAJ et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016.
- Martens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
- Irie J et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020.
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
